Mr. Chair, thank you for that question and further clarification.
I would just emphasize that we have to look at the point in time at which these different organizations are communicating. Right now it's not just Canada. The United States, the European regulatory agencies and indeed countries very similar to our own—which have access, of course, to the manufacturers' data and their own epidemiologic information—have all recommended the bivalent vaccines.
That may be something we need to consider. I really want to thank the committee for trying to bring this point out so that Canadians can understand. Health Canada, which is not here today, our regulator, has very strong safety and effectiveness criteria that they bring to bear. They do talk to the FDA, the European Medicines Agency and the United Kingdom, for example, and they exchange information very closely. So they do share the data and they have similar data in front of them.